Arcus Biosciences (RCUS) Misses Q1 EPS by 12c
Tweet
Share
E-mail
Get Alerts RCUS Hot Sheet
Join SI Premium – FREE
Arcus Biosciences (NYSE: RCUS) reported Q1 EPS of ($1.14), $0.12 worse than the analyst estimate of ($1.02). Revenue for the quarter came in at $28 million versus the consensus estimate of $38.61 million.
For earnings history and earnings-related data on Arcus Biosciences (RCUS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Virtu Financial posts Q2 2026 preliminary results, seeks $400M loan
- Runway Growth plans stock buyback amid discount to NAV
- RXO partners with Highway to improve carrier vetting and load security
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
